1. Home
  2. RXT vs SLN Comparison

RXT vs SLN Comparison

Compare RXT & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RXT
  • SLN
  • Stock Information
  • Founded
  • RXT 1998
  • SLN 1994
  • Country
  • RXT United States
  • SLN United Kingdom
  • Employees
  • RXT N/A
  • SLN N/A
  • Industry
  • RXT EDP Services
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RXT Technology
  • SLN Health Care
  • Exchange
  • RXT Nasdaq
  • SLN Nasdaq
  • Market Cap
  • RXT 280.1M
  • SLN 299.4M
  • IPO Year
  • RXT 2020
  • SLN N/A
  • Fundamental
  • Price
  • RXT $1.26
  • SLN $4.81
  • Analyst Decision
  • RXT Hold
  • SLN Buy
  • Analyst Count
  • RXT 5
  • SLN 5
  • Target Price
  • RXT $1.58
  • SLN $32.60
  • AVG Volume (30 Days)
  • RXT 764.7K
  • SLN 61.8K
  • Earning Date
  • RXT 08-07-2025
  • SLN 08-07-2025
  • Dividend Yield
  • RXT N/A
  • SLN N/A
  • EPS Growth
  • RXT N/A
  • SLN N/A
  • EPS
  • RXT N/A
  • SLN N/A
  • Revenue
  • RXT $2,693,100,000.00
  • SLN $27,169,000.00
  • Revenue This Year
  • RXT N/A
  • SLN N/A
  • Revenue Next Year
  • RXT $1.48
  • SLN N/A
  • P/E Ratio
  • RXT N/A
  • SLN N/A
  • Revenue Growth
  • RXT N/A
  • SLN 22.28
  • 52 Week Low
  • RXT $1.00
  • SLN $1.97
  • 52 Week High
  • RXT $3.41
  • SLN $20.48
  • Technical
  • Relative Strength Index (RSI)
  • RXT 52.70
  • SLN 34.88
  • Support Level
  • RXT $1.14
  • SLN $4.91
  • Resistance Level
  • RXT $1.31
  • SLN $5.34
  • Average True Range (ATR)
  • RXT 0.08
  • SLN 0.48
  • MACD
  • RXT 0.01
  • SLN -0.05
  • Stochastic Oscillator
  • RXT 79.55
  • SLN 0.71

About RXT Rackspace Technology Inc.

Rackspace Technology Inc is an end-to-end, hybrid, multi cloud technology services company. It designs, builds and operates its customers' cloud environments across all technology platforms, irrespective of technology stack or deployment model. The company's solutions include Application Services; Data; Colocation; Cloud; Managed Hosting; Professional Services; and Security & Compliance. It operates in segments namely, Private Cloud, and Public Cloud. It generates revenue through the sale of consumption-based contracts for its service offerings and from the sale of professional services related to designing and building custom solutions.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

Share on Social Networks: